Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00461045 · OUTCOME

Number of Cycles of Marizomib (MRZ)

Phase 2 Clinical Trial of NPI-0052 in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma · Source last updated 2017-12-19

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEAN
Unit
cycles
Interval / dispersion
Standard Deviation
Time frame
Through study completion, an average of 6.09 weeks.

Groups in this outcome

MRZ 0.5 mg/m^2

Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
MRZ 0.5 mg/m^215

Reported measurements

Source class 1
Values in cycles · Interval/dispersion: Standard Deviation
GroupValueSpreadLowerUpperComment
MRZ 0.5 mg/m^22.61.45Not reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        spread
        1.45
        value
        2.6
denoms
  1. counts
    1. group Id
      OG000
      value
      15
    units
    Participants
dispersion Type
Standard Deviation
groups
  1. description
    Twice-weekly dosing with 2-hour IV infusions on days 1,4,8, and 11 of 3-week cycles
    id
    OG000
    title
    MRZ 0.5 mg/m^2
param Type
MEAN
reporting Status
POSTED
time Frame
Through study completion, an average of 6.09 weeks.
title
Number of Cycles of Marizomib (MRZ)
type
SECONDARY
unit Of Measure
cycles

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice